ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
11.47 USD   +5.62%
08/01ALX Oncology Receives FDA Fast-Track Designation for Head, Neck Cancer Drug
MT
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped from Russell Small Cap Comp Growth Index

06/24/2022 | 12:00am EDT

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped from Russell Small Cap Comp Growth Index


© S&P Capital IQ 2022
All news about ALX ONCOLOGY HOLDINGS INC.
08/01ALX Oncology Receives FDA Fast-Track Designation for Head, Neck Cancer Drug
MT
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
CI
06/29ALX Oncology Secures FDA Orphan Drug Designation for Evorpacept
MT
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
AQ
06/29ALX Oncology's Evorpacept Gets FDA Designation for Leukemia
DJ
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell 3000 Growth Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell Microcap Value Index
CI
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -110 M - -
Net cash 2022 277 M - -
P/E ratio 2022 -4,25x
Yield 2022 -
Capitalization 467 M 467 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 44
Free-Float 62,8%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 11,47 $
Average target price 43,25 $
Spread / Average Target 277%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-46.63%467
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093